• The ester moiety is a promising structural motif

  2022-05-04

  

  The ester moiety is a promising structural motif at the C-3 position for the development of drug-like molecules. However, the labile C-3 ester bond impels these derivate to be susceptible to plasmatic degradation by esterases and this is natural steroidal metabolic process [39,40]. Hence, the isoste

• In this study with the use

  2022-05-04

  

  In this study, with the use of 13C515N2-labeled glutamine, we observed that 13C515N2-labeled glutamine produces a wide range of NAAG isotopologues and its precursors: NAA and glutamate. The NAAG production from glutamine is consistently more elevated in MYC-ON lymphoma and OVCAR4 compared to MYC-OFF

• br Genetic rescue of GluR A dependent

  2022-05-04

  

  Genetic rescue of GluR-A-dependent spatial working memory Spatial working memory performance in GluR-A−/− mice can be restored by the forebrain-specific motilin receptor agonist of GluR-A subunits labeled with green-fluorescent protein (GFP) on an otherwise GluR-A knockout background (Schmitt et

• rotenone br Conclusion br Acknowledgment This study was supp

  2022-05-04

  

  Conclusion Acknowledgment This study was supported by grants from the Excellence Initiative of the German federal and state governments, the Else Kröner-Fresenius Foundation and the German Society for Cardiology (DGK) to F.K. and grants from the Deutsche Forschungsgemeinschaft (SFB TRR 219 M-0

• br A small conductance chloride

  2022-05-04

  

  A small conductance chloride channel (SCC) In addition to the above-described channels, a 5pS SCC has been encountered in electrophysiological recordings. This channel, exhibiting long periods of opening separated by long intervals of closing, showed the same characteristics as the SCC described

• br Involvement of gap junctions and Panx in spinal cord

  2022-05-04

  

  Involvement of gap junctions and Panx1 in spinal cord processing of pain information Several studies indicated that GJs in the CNS contribute to pain. A common finding in such studies is that intrathecal administration of GJ blocker attenuates pain behavior. For example, intrathecal CBX attenuate

• We next investigated whether pharmaceutical inhibition of th

  2022-05-04

  

  We next investigated whether pharmaceutical inhibition of the PI3K pathway was synergistic with FGFR inhibition using BKM120, a pan-PI3K inhibitor with modest antitumor activity in cancer patients, as a single agent. We found that RT112 (- translocation) and JMSU1 ( amplification) were not signifi

• Compared to a large database

  2022-05-04

  

  Compared to a large database of NSCLC samples matched for disease type, many of the frequently altered genes were similar to those seen in this series of FGFR fusion-positive samples; however, there were notable exceptions. As expected, alterations in known NSCLC drivers (KRAS and EGFR) were signifi

• Next we were interested in replacing

  2022-04-29

  

  Next, we were interested in replacing the ketobenzimidazole fragment of our inhibitors with a noncarbonyl bearing heterocycle. We reasoned that if we could replace the carbonyl while maintaining comparable FAAH inhibition, it would provide evidence for a noncovalent mechanism of action. Thus, we eva

• br Acknowledgments I thank Takeshi Sakaba

  2022-04-29

  

  Acknowledgments I thank Takeshi Sakaba for critical reading of the manuscript and helpful comments. This work was supported by JSPS/MEXT KAKENHI Grant Numbers 17K19466, 17H03548. Introduction The oral route of drug application is the main route in pharmacology since it is easy to handle and o

• Glycine released from astrocytes as well as

  2022-04-29

  

  Glycine released from astrocytes as well as neurons is also known as a co-agonist of NMDAR (Roux and Supplisson, 2000). Neuronal glycine in mouse hippocampus might be released from glutamatergic terminals (Muller et al., 2013) that express functional sigma 1 receptor receptors (Rodriguez et al., 19

• A phase I clinical trial has been completed for

  2022-04-29

  

  A phase I clinical trial has been completed for assessing CEP-26401 in cognitive impairment in healthy individuals without disclosing any results (NCT01903824). Although CEP-26401 is under clinical trial study, several projects are in progress for synthesizing novel irdabisant analogs in order to im

• br Conclusion br Author contributions br Ethics approval

  2022-04-29

  

  Conclusion Author contributions Ethics approval Competing interests Introduction VHL is a well-known tumor suppressor and works as a target recruitment subunit of an E3 ubiquitin ligase complex that recruits hydroxylated hypoxia inducible factor α (HIF-α) for proteasomal degradation u

• Theoretically the majority of resistance mechanisms identifi

  2022-04-29

  

  Theoretically, the majority of resistance mechanisms identified so far could be targeted by compounds that are already available, such as inhibitors of ER, PIK3CA/mTOR or FGFR1. However, the potential therapeutic advantage of combining these agents with standard HER2-targeting treatments must be wei

• In conclusion while class I HDAC inhibitors isoform

  2022-04-29

  

  In conclusion, while class I HDAC inhibitors, isoform-specific HDAC3 and HDAC6 inhibitors may represent novel therapeutic targets for prevention of clinical AF onset and progression, the specific HDAC3 and HDAC6 inhibitors may be more appropriate because of their limited off-targets effects. Besides

15469 records 416/1032 page Previous Next First page 上5页 416417418419420 下5页 Last page